Following this activity, participants should be able to: (1) Discuss the new and emerging therapeutic options for patients with non muscle-invasive bladder cancer and how they can be integrated into clinical practice. (2) Describe the recent updates to the systemic therapy options for muscle-invasive bladder cancer as well as disease characteristics that may guide treatment choice. (3) Review the results of recent clinical trials involving non muscle-invasive and muscle-invasive bladder cancer and their potential impact on treatment planning.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 3025 Chemical Road
Pricing
CME included with membership
| Free CME Activity | Free |
| Paid Activity (e.g. Breast/Lung Cancer Congress recordings) | $50 |
| Paid Activity (e.g. Hematologic Malignancies Congress recording) | $90 |
Collected from the provider’s public pages · source
Specialties served/covered
- Addiction Medicine
- Adolescent Medicine
- Anatomic & Clinical Pathology
- Colon & Rectal Surgery
- Communication & Shared Decision-Making
- Dermatopathology
- Evidence-Based Medicine & Research
- Gastroenterology
- Gastrointestinal Surgery
- General Surgery
- Geriatric Medicine
- Gynecologic Oncology
- Head & Neck Surgery
- Health Equity & Inclusion
- Hematology
- Hospice & Palliative Medicine
- Medical Genetics & Genomics
- Medical Leadership & Administration
- Medical Oncology
- Nephrology
- Neurology
- Obstetrics & Gynecology
- Pain Medicine
- Pediatric Hematology-Oncology
- Practice Management & Ethics
- Pulmonary Disease
- Radiation Oncology
- Surgical Oncology
- Thoracic Surgery
- Transplant Hepatology
- Urological Oncology
- Urology
- Cardio-Vascular
- Cross-Specialty
- ENT & Head Neck
- GI & Liver
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pain & Palliative
- Pathology & Lab
- Primary care
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- On-demand / recorded video
- Credit · Up to 1 credit
- Commercial Support
-
ReleasedJul 31, 2026
-
Last day to claim creditJul 28, 2027 10 months left
-
Learner’s Digest International (TM) Management of Non-Muscle Invasive Bladder Cancer
-
RedMedEd +1 Biomarker-Driven Treatment of Muscle-Invasive Bladder Cancer
-
University of Alabama at Birmingham Marnix E. Heersink School of Medicine UAB MedCast: Medical Innovation – Understanding Non-Muscle Invasive Bladder Cancer
-
National Comprehensive Cancer Network Archived NCCN Tumor Boards: Optimizing Clinical Decision-Making for Resectable Non-Small Cell Lung Cancer
-
National Comprehensive Cancer Network Recorded Presentation from the NCCN 2026 Annual Conference: Genitourinary Cancers
-
National Comprehensive Cancer Network Recorded Presentation from the NCCN 2026 Annual Conference: Gastrointestinal Cancers
